Engineering Stent Based Delivery System for Esophageal Cancer Using Docetaxel

Shaikh, Mohsin; Choudhury, Namita Roy; Knott, Robert; Garg, Sanjay

doi:10.1021/mp500851u

Cited by 23 publications

(27 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…DTX-loaded PU films were prepared by the solvent casting method described by Shaikh et al (6). In brief, appropriate amount of PUS and DTX were dissolved in tetrahydrofuran (THF) and cast on a Petri plate.…”

Section: Formulation Preparationmentioning

confidence: 99%

“…Formulations 3 and 4 showed sustained release as compared to formulations 1 and 2 (6). Considering the benefit of long-term activity against the tumors, formulation 3 and 4 were selected for initial in vivo studies.…”

Section: Formulation Modificationmentioning

confidence: 99%

“…Formulations 1m and 2m (square piece of a 1-cm 2 area, n = 3) were characterized as described previously (6). Physical characterization included weight and thickness variation.…”

Section: Characterization Of the Modified Formulationmentioning

confidence: 99%

“…HPLC method was used for the assay and release sample analysis was as described by Shaikh et al (6). Briefly, Zorbax Eclipse XDB C18 column (4.6 × 150-mm dimensions and 3.5-μm particle size) was used on a Shimadzu instrument equipped with DGU-20AS degasser, LC-20AD liquid chromatograph, SIL-20A HT autosampler and SPD M20A diode array detector.…”

Section: Characterization Of the Modified Formulationmentioning

confidence: 99%

“…These films were prepared in a bilayer configuration using DTXloaded and blank film. Bilayer formulations have been shown to provide sustained unidirectional release over a month (6). In the present investigation, the formulations were tested for in vitro activity in cell types representing EC from both histological types, viz, OE-19 (ACA) and OE-21 (SCC).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

In Vitro and In Vivo Assessment of Docetaxel Formulation Developed for Esophageal Stents

et al. 2016

Self Cite

View full text Add to dashboard Cite

Abstract. Esophageal cancer (EC) mostly affects the elderly population and is frequently diagnosed at an advanced stage. Self-expanding metal stents (SEMS) are the most popular mode of palliation, but they are associated with reocclusion caused by tumor growth. To overcome this problem, docetaxel (DTX)-loaded polyurethane formulations were prepared for stent application. The films were evaluated against the cancer cell lines, OE-19 and OE-21, and normal esophageal cell line Het-1A. The DTX and the formulations were evaluated in vitro for the cytotoxicity and in vivo in nude mice. It was found that DTX and the formulations have a weak activity against the EC cell lines and an even weaker activity against Het-1A cell line. Preliminary in vivo studies showed skin toxicity in nude mice necessitating modification of the formulation. Reevaluation in a mouse xenograft model resulted in toxicity at high dose formulations while the low dose formulation exhibited modest advantage over commercial IV formulation; however, there was no significant difference between the commercial IV and blank formulation. DTX combination with an anti-cancer agent having complementary mode of action and non-overlapping toxicity could yield better outcome in future.

show abstract

Section: Formulation Preparationmentioning

confidence: 99%

Section: Formulation Modificationmentioning

confidence: 99%

“…Formulations 1m and 2m (square piece of a 1-cm 2 area, n = 3) were characterized as described previously (6). Physical characterization included weight and thickness variation.…”

Section: Characterization Of the Modified Formulationmentioning

confidence: 99%

Section: Characterization Of the Modified Formulationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

In Vitro and In Vivo Assessment of Docetaxel Formulation Developed for Esophageal Stents

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

Investigation Outcomes of Laparogastroscopy – An Alternative Palliative Method of Endoscopic Stenting in Advanced or Inoperable Esophageal Cancer – In Patients with and Without Prior Chemo and Radiotherapy

Lupu-Petria,

Sabău,

Sabău

et al. 2024

IFMBE Proceedings

View full text Add to dashboard Cite

Stenting in Palliation of Unresectable Esophageal Cancer

Włodarczyk

Kużdżał

2018

World j. surg.

View full text Add to dashboard Cite

BackgroundThe aim of this study was to analyze the safety and effectiveness of stenting using partially covered self-expandable stents in palliation of dysphagia in patients with unresectable esophageal cancer.MethodsRetrospective analysis of hospital records of all patients who underwent esophageal stenting in the period 2008–2015 was performed. The study included patients with unresectable esophageal and esophagogastric cancer.ResultsThere were 442 patients included. Mean age was 56 years (range 28–89), and 379 were males. In 40 (9.0%) patients, stenting was performed in the cervical, in 150 (39.3%)—in the middle thoracic, in 141 (31.9%)—in lower thoracic esophagus and in 111 (25.1%)—in the esophagogastric junction. Stenting resulted in significant alleviation of dysphagia grade (3.0 vs. 1.0, p = 0.00001). During the follow-up, 55 (12.4%) patients experienced recurrent dysphagia due to tumor or granulation tissue overgrowth, and in 18 (4.1%) patients, migration of the stent occurred, for which an independent risk factor was adjuvant chemo- and/or radiation therapy (p = 0.001). Minor complications included chest pain (54.5%), delayed complete stent expansion (12.0%), feeling of a foreign body (25.3%), hiccup (1.6%), gastroesophageal reflux (45.6%) and post-discharge pneumonia (2.5%). A feeling of a foreign body in the esophagus was significantly more common after stenting of the cervical esophagus (p = 0.0001), and hiccup was more common after stenting of the esophagogastric junction (p = 0.02). Major complications included bleeding (1.3%), respiratory insufficiency (0.7%), esophageal perforation (0.9%) and irregular heartburn (2.3%). Overall procedure-related mortality was 0.4%. The median survival time was 117.8 days (range 2–732).ConclusionsStenting is an effective procedure in relieving dysphagia in patients with unresectable malignant esophageal stenosis and is associated with low rate of postoperative and long-term complications.

show abstract

Engineering Stent Based Delivery System for Esophageal Cancer Using Docetaxel

Cited by 23 publications

References 52 publications

In Vitro and In Vivo Assessment of Docetaxel Formulation Developed for Esophageal Stents

In Vitro and In Vivo Assessment of Docetaxel Formulation Developed for Esophageal Stents

Investigation Outcomes of Laparogastroscopy – An Alternative Palliative Method of Endoscopic Stenting in Advanced or Inoperable Esophageal Cancer – In Patients with and Without Prior Chemo and Radiotherapy

Stenting in Palliation of Unresectable Esophageal Cancer

Contact Info

Product

Resources

About